8-K: Alnylam Pharmaceuticals Reports Strong Q1 2026 Results

Alnylam Pharmaceuticals announced first quarter 2026 financial results, achieving over $1 billion in quarterly product revenues for the first time, driven by significant growth in TTR therapies.

Summary

• Alnylam Pharmaceuticals reported first quarter 2026 financial results, marking a significant milestone with over $1 billion in global net product revenues for the first time.
• Total net product revenues reached $1,036 million, a 121% increase compared to Q1 2025.
• Total TTR net product revenues, primarily from AMVUTTRA and ONPATTRO, were $910 million, showing a 153% growth year-over-year.
• AMVUTTRA revenues alone were $890 million, a 187% increase from Q1 2025.
• Total Rare net product revenues from GIVLAARI and OXLUMO were $126 million, a 15% increase.
• The company reiterated its full-year 2026 financial guidance, expecting total net product revenues between $4,900 million and $5,300 million.
• Pipeline progress includes advancing Phase 3 trials and initiating a Phase 1 study for an obesity and weight management program.
• New data presented at ACC.26 supports vutrisiran as a first-line treatment for ATTR-CM, and collaborations with Viz.ai and AHA aim to improve ATTR-CM diagnosis and care.

Sentiment

Score: 9

Explanation: StockSavvy.ai views this as a very positive report, with record revenues, strong growth across key products, and reiterated guidance, indicating robust operational performance and a healthy financial position.

Positives

• Achieved over $1 billion in global net product revenues for the first time in Q1 2026.
• Total net product revenues grew by 121% to $1,036 million in Q1 2026 compared to Q1 2025.
• Total TTR net product revenues increased by 153% to $910 million in Q1 2026.
• AMVUTTRA net product revenues surged by 187% to $890 million in Q1 2026.
• Total Rare net product revenues grew by 15% to $126 million in Q1 2026.
• Reiterated strong full-year 2026 financial guidance for total net product revenues ($4,900M - $5,300M) and TTR net product revenues ($4,400M - $4,700M).
• Enrollment in the nucresiran TRITON-CM Phase 3 study is proceeding faster than anticipated.
• Cash, cash equivalents, and marketable securities increased to $3.0 billion as of March 31, 2026.

Negatives

• ONPATTRO net product revenues decreased by 59% to $20 million in Q1 2026 compared to Q1 2025.
• Net revenues from collaborations decreased by 17% in Q1 2026 compared to Q1 2025, primarily due to a $30 million payment recognized in March 2025 related to an agreement amendment.
• Cost of goods sold as a percentage of net product revenues increased to 20.0% in Q1 2026 from 15.0% in Q1 2025.
• GAAP Income from operations was $268.6 million in Q1 2026, a significant increase from $18.1 million in Q1 2025, but the increase is largely driven by revenue growth rather than cost control.

Risks

• The company's ability to successfully execute on its Alnylam 2030 strategy.
• Alnylam's ability to successfully launch, market, and sell its approved products globally, including AMVUTTRA.
• The pre-clinical and clinical results for Alnylam's product candidates, and the ability to demonstrate efficacy and safety.
• Actions or advice of regulatory agencies and Alnylam's ability to obtain and maintain regulatory approval for its product candidates.
• Delays, interruptions, or failures in the manufacture and supply of Alnylam's marketed products or its product candidates.
• Obtaining, maintaining, and protecting intellectual property.
• Alnylam's dependence on third parties for the development and commercialization of certain products.
• The risk of future litigation and government investigations.

Future Outlook

Alnylam reiterates its full-year 2026 financial guidance, projecting total net product revenues between $4,900 million and $5,300 million, and total TTR net product revenues between $4,400 million and $4,700 million. The company anticipates multiple pipeline programs to have key clinical readouts in the second half of 2026, supporting long-term growth towards Alnylam 2030 goals.

Management Comments

• "2026 is off to a strong start for Alnylam with the end of the first quarter marking one year since the U.S. launch of AMVUTTRA for ATTR-CM, and also representing a significant financial milestone with the achievement of over $1 billion in quarterly product revenues for the first time in our history," said Yvonne Greenstreet, M.D., Chief Executive Officer of Alnylam.
• "At the same time, we continued to advance our deep and high-value pipeline of RNAi therapeutics, progressing three ongoing Phase 3 trials, and initiating a Phase 1 study for our first adipose-targeted program for obesity and weight management."
• "Together, this represents important initial progress toward our Alnylam 2030 goals of achieving global TTR leadership, driving growth through innovation, and scaling with financial discipline as we work to deliver substantial patient impact and create long-term value."

Industry Context

StockSavvy.ai notes that Alnylam's strong Q1 2026 performance, particularly the significant growth in TTR therapies, highlights the company's leadership in the RNAi therapeutics space and its successful commercialization strategy. The continued pipeline progress and strategic collaborations underscore the industry trend towards targeted therapies and early disease diagnosis.

Comparison to Industry Standards

• Alnylam's Q1 2026 total net product revenue growth of 121% significantly outpaces the typical growth rates seen in the broader biopharmaceutical industry, which often range from single digits to low double digits for established products.
• The 153% growth in Total TTR net product revenues, driven by AMVUTTRA's 187% surge, demonstrates exceptional market penetration and demand for Alnylam's ATTR treatments, setting a high benchmark for rare disease drug commercialization.
• While specific competitor data for Q1 2026 is not provided, Alnylam's performance in the ATTR market, where it competes with other therapies, indicates a dominant position and strong competitive advantage.
• The company's ability to achieve over $1 billion in quarterly product revenues for the first time is a significant financial milestone, placing it among the top-tier biopharmaceutical companies in terms of revenue generation for specific therapeutic areas.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, record revenues, and reiterated guidance, suggesting potential for increased shareholder value.
• Employees: Continued investment in R&D and SG&A suggests ongoing growth and potential for career development within the company.
• Patients: Continued progress in clinical trials and strategic collaborations for ATTR-CM aim to improve patient outcomes and access to treatments.
• Partners (e.g., Roche, Regeneron): Continued collaboration revenue streams are maintained, with potential for future product development and commercialization.

Next Steps

• Complete enrollment in the cAPPricorn-1 Phase 2 clinical trial of mivelsiran in patients with cerebral amyloid angiopathy in H1 2026.
• Initiate a Phase 2 trial of mivelsiran in patients with Alzheimer's disease in H1 2026.
• Initiate a Phase 2 clinical trial of ALN-6400 in a second bleeding disorder in H1 2026.
• Announce clinical data from several pipeline programs in H2 2026, including Phase 1/2 trials for ALN-6400 and ALN-2232, and a Phase 1 trial for ALN-HTT02.
• Host the 10th RNAi Roundtable series later in 2026 to discuss pipeline progress.

Key Dates

Recommendation

The company delivered exceptional Q1 2026 results, surpassing revenue expectations and demonstrating significant year-over-year growth, particularly in its TTR franchise. With reiterated strong full-year guidance, a robust pipeline showing progress, and strategic initiatives to improve patient care, Alnylam presents a compelling investment case with substantial growth potential.

Keywords

Alnylam Pharmaceuticals, RNAi therapeutics, ATTR-CM, ATTR-PN, AMVUTTRA, ONPATTRO, GIVLAARI, OXLUMO